203 related articles for article (PubMed ID: 24302677)
1. A population-based evaluation of cervical screening in the United States: 2008-2011.
Cuzick J; Myers O; Hunt WC; Robertson M; Joste NE; Castle PE; Benard VB; Wheeler CM;
Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):765-73. PubMed ID: 24302677
[TBL] [Abstract][Full Text] [Related]
2. Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.
Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LC; Cuzick J; Myers O; Castle PE; Wheeler CM;
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):36-42. PubMed ID: 26518316
[TBL] [Abstract][Full Text] [Related]
3. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
[TBL] [Abstract][Full Text] [Related]
4. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
5. Pooled analysis of the performance of liquid-based cytology in population-based cervical cancer screening studies in China.
Pan QJ; Hu SY; Zhang X; Ci PW; Zhang WH; Guo HQ; Cao J; Zhao FH; Lytwyn A; Qiao YL
Cancer Cytopathol; 2013 Sep; 121(9):473-82. PubMed ID: 23907807
[TBL] [Abstract][Full Text] [Related]
6. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
[TBL] [Abstract][Full Text] [Related]
7. [Human Papilloma Virus (HPV), cervical cancer incidence and screening uptake: differences among Northern, Central and Southern Italy].
Giorgi Rossi P; Chini F; Borgia P; Guasticchi G; Carozzi FM; Confortini M; Angeloni C; Buzzoni C; Buonaguro FM;
Epidemiol Prev; 2012; 36(2):108-19. PubMed ID: 22706361
[TBL] [Abstract][Full Text] [Related]
8. High-grade squamous intraepithelial lesion in women aged <30 years has a prevalence pattern resembling low-grade squamous intraepithelial lesion.
Vale DB; Westin MC; Zeferino LC
Cancer Cytopathol; 2013 Oct; 121(10):576-81. PubMed ID: 23765869
[TBL] [Abstract][Full Text] [Related]
9. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
[TBL] [Abstract][Full Text] [Related]
10. Frequency of cervical smear abnormalities within 3 years of normal cytology.
Sawaya GF; Kerlikowske K; Lee NC; Gildengorin G; Washington AE
Obstet Gynecol; 2000 Aug; 96(2):219-23. PubMed ID: 10908766
[TBL] [Abstract][Full Text] [Related]
11. A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States.
Landy R; Mathews C; Robertson M; Wiggins CL; McDonald YJ; Goldberg DW; Scarinci IC; Cuzick J; Sasieni PD; Wheeler CM
Gynecol Oncol; 2020 Nov; 159(2):344-353. PubMed ID: 32977987
[TBL] [Abstract][Full Text] [Related]
12. Unindicated cervical cancer screening in adolescent females within a large healthcare system in the United States.
Hosier H; Sheth SS; Oliveira CR; Perley LE; Vash-Margita A
Am J Obstet Gynecol; 2021 Dec; 225(6):649.e1-649.e9. PubMed ID: 34256029
[TBL] [Abstract][Full Text] [Related]
13. Human papilloma virus screening by hybrid capture II in Chinese women of Jiangsu Province.
Wang QW; Xu PZ; Zhang B; Dong YS; Yang YQ; Cao F; Yu B
West Indian Med J; 2010 Oct; 59(5):469-72. PubMed ID: 21473391
[TBL] [Abstract][Full Text] [Related]
14. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.
Latsuzbaia A; Hebette G; Fischer M; Arbyn M; Weyers S; Vielh P; Schmitt F; Mossong J
Diagn Cytopathol; 2017 May; 45(5):384-390. PubMed ID: 28247516
[TBL] [Abstract][Full Text] [Related]
15. Protection against squamous cell carcinoma and cervical adenocarcinoma afforded by cervical cytology screening: a cross-sectional study.
Vale DB; Braganca JF; Morais SS; Zeferino LC
Int J Gynecol Cancer; 2014 Feb; 24(2):321-8. PubMed ID: 24407579
[TBL] [Abstract][Full Text] [Related]
16. How many cervical cancer cases can potentially be prevented using a more sensitive screening test at young age?
de Kok IM; van Rosmalen J; Rozemeijer K; Penning C; van Ballegooijen M
Int J Cancer; 2014 Jan; 134(2):460-6. PubMed ID: 23824905
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of cervical screening after age 60 years according to screening history: Nationwide cohort study in Sweden.
Wang J; Andrae B; Sundström K; Ploner A; Ström P; Elfström KM; Dillner J; Sparén P
PLoS Med; 2017 Oct; 14(10):e1002414. PubMed ID: 29065127
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus triage for young women with atypical squamous cells of undetermined significance.
Wright JD; Rader JS; Davila R; Powell MA; Mutch DG; Gao F; Gibb RK
Obstet Gynecol; 2006 Apr; 107(4):822-9. PubMed ID: 16582118
[TBL] [Abstract][Full Text] [Related]
19. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
20. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S78-84. PubMed ID: 23519309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
